To improve the lives of patients by transforming subsets of cancer from acute diseases to manageable conditions. Blueprint Medicines’ will execute on this by systematically developing highly selective drugs, and combinations of these drugs, against clearly defined aberrant driver and resistance mechanisms that are being elucidated through cancer sequencing efforts and functional studies.